Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195

November 14, 2017
STAMFORD, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that…

Arcus Biosciences Announces $107 Million Series C Financing Led by GV and Initiation of Two Clinical Trials

November 13, 2017
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today the completion of a $107 million Series C financing. This…

Meet a VC: Steve Elms & Drew Schiff of Aisling Capital

November 8, 2017
Recently, Jill Malandrino, Global Markets Reporter, Nasdaq sat down with Steve Elms and Drew Schiff, Managing Partners at Aisling Capital to discuss their investment focus and strategies.